Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of LY3526318, and to Investigate the Effect of LY3526318 on Metformin and Simvastatin Pharmacokinetics in Healthy Male Japanese Participants

Next Previous
Search
Trial Profile

A Phase I, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of LY3526318, and to Investigate the Effect of LY3526318 on Metformin and Simvastatin Pharmacokinetics in Healthy Male Japanese Participants

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LY 3526318 (Primary)
  • Indications Neuropathic pain; Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 06 Jan 2023 Planned End Date changed from 4 Mar 2023 to 8 Dec 2022.
    • 06 Jan 2023 Planned primary completion date changed from 4 Mar 2023 to 8 Dec 2022.
    • 06 Jan 2023 Planned initiation date changed from 21 Nov 2022 to 22 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top